Amalgamated Financial’s Supernus Pharmaceuticals SUPN Stock Holding History

Amalgamated Financial’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$756K	Buy	+23,379	New	+$717K	0.01%	1319

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Amalgamated Financial's SUPN Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Supernus Pharmaceuticals (SUPN) in Q1 2022: 23,379 shares worth $756K. The stake represents 0.01% of the portfolio and ranks #1319 among its holdings.

230 funds tracked by Wall St. Rank hold SUPN as of Q1 2022.

Amalgamated Financial held 23,379 shares of Supernus Pharmaceuticals worth $756K as of Q1 2022.
Supernus Pharmaceuticals was a new Amalgamated Financial position in Q1 2022.
Supernus Pharmaceuticals made up 0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1319 holding.
230 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.